GEA
UBX

Glen Eagle Advisors’s Unity Biotechnology UBX Stock Holding History

Glen Eagle Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,942
Closed -$746 – 1148
2025
Q2 		$746 Buy
1,942
+838
+76% +$718 ﹤0.01% 956
2025
Q1 		$1.15K Hold
1,104
– – ﹤0.01% 916
2024
Q4 		$1.08K Hold
1,104
– – ﹤0.01% 954
2024
Q3 		$1.62K Hold
1,104
– – ﹤0.01% 936
2024
Q2 		$1.49K Hold
1,104
– – ﹤0.01% 943
2024
Q1 		$1.81K Hold
1,104
– – ﹤0.01% 919
2023
Q4 		$2.13K Hold
1,104
– – ﹤0.01% 857
2023
Q3 		$2.65K Sell
1,104
-1
-0.1% -$3 ﹤0.01% 817
2023
Q2 		$2.82K Buy
1,105
+681
+161% +$1.8K ﹤0.01% 822
2023
Q1 		$691 Hold
424
– – ﹤0.01% 980
2022
Q4 		$1.16K Sell
424
-1
-0.2% -$3 ﹤0.01% 995
2022
Q3 		$1.68K Hold
425
– – ﹤0.01% 890
2022
Q2 		$2.4K Buy
425
+134
+46% +$1.12K ﹤0.01% 810
2022
Q1 		$3.26K Buy
291
+237
+439% +$2.66K ﹤0.01% 758
2021
Q4 		$785 Hold
54
– – ﹤0.01% 872
2021
Q3 		$1.61K Buy
54
+23
+74% +$812 ﹤0.01% 951
2021
Q2 		$1.44K Hold
31
– – ﹤0.01% 956
2021
Q1 		$1.86K Buy
+31
New +$2.11K ﹤0.01% 885

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Glen Eagle Advisors's UBX Position: Q3 2025 in Review

Glen Eagle Advisors sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 1,942 shares — an estimated $746 sold.

Glen Eagle Advisors first reported a position in UBX in Q1 2021 and held it in 18 quarters. The position peaked at $3.26K in Q1 2022. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Glen Eagle Advisors reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Glen Eagle Advisors sold 1,942 Unity Biotechnology shares in Q3 2025, an estimated $746.
  • Glen Eagle Advisors first reported a position in Unity Biotechnology in Q1 2021 and held it in 18 quarters.
  • Glen Eagle Advisors's Unity Biotechnology position peaked at $3.26K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Glen Eagle Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.